Abbott Faces Jury Award of at Least $53 Million in Infant Formula Lawsuit

Abbott Laboratories announced it faces a jury award of at least $53 million in a lawsuit brought by four mothers. The plaintiffs claimed that the company hid risks related to its premature-infant formula, which they alleged can cause necrotizing enterocolitis, a bowel disease. This condition leads to serious health issues in frail, premature babies.

The lawsuit stems from the use of Abbott's specialized nutrition products designed for premature infants. Necrotizing enterocolitis involves inflammation and damage to the intestines, often requiring surgical intervention and long-term medical care. Premature infants, born before 37 weeks gestation, are particularly susceptible due to underdeveloped digestive systems.

the Case The four mothers filed the suit asserting that Abbott failed to disclose potential links between its formula and the disease.

According to @business, the jury determined that the company withheld information about these risks. The award covers compensatory damages for the affected families, with the exact total to be finalized. This case highlights ongoing scrutiny of infant formula manufacturers regarding product safety.

U.S. Food and Drug Administration monitor formula compositions and adverse event reports. Previous investigations have examined cow's milk-based formulas versus human milk in preventing necrotizing enterocolitis.

The plaintiffs represent families whose infants developed the condition after using Abbott's formula.

Necrotizing enterocolitis affects approximately 10% of very low birth weight infants, per medical literature, leading to high hospitalization rates and mortality risks up to 30%. Affected families face lifelong medical needs, including potential developmental delays. Abbott, a major producer of infant nutrition products, supplies hospitals and consumers worldwide.